This is an open-label, single-arm, multi-center Phase II trial of AB-16B5 in combination with
docetaxel in previously treated subjects with metastatic non-small cell lung cancer who have
experienced disease progression following treatment with a platinum-containing doublet
treatment and an anti-PD1 or PD-L1 immune checkpoint antibody, administered simultaneously or
sequentially. Approximately 40 subjects will be enrolled in this trial and receive AB-16B5 at
a dose of 12 mg/kg once weekly on Days 1, 8 and 15 combined with docetaxel at a dose of 75
mg/m2 once every 3 weeks on Day 1. One cycle of treatment will consist of 21 days (3 weeks).
The safety profile of the AB-16B5 and docetaxel combination will be examined during a safety
lead-in period with the first 8 subjects completing one cycle of treatment. No dose
escalation will be performed but a decision to de-escalate the AB-16B5 dose could be made
using the modified toxicity probability interval method.
Subjects will be evaluated every 6 weeks with radiographic imaging to assess response to
treatment using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria for
determination of the objective response rate (ORR) and progression free survival (PFS).
Paired tumor biopsies (pre-treatment and on-treatment) will be collected in all subjects.
Study treatment will continue until there is evidence of disease progression,
treatment-related adverse events of unacceptable severity, subject request for
discontinuation or Investigator determination that further treatment is not in the subject's
best interest. Treatment through progression will be allowed if the Investigator considers
the subject to be clinically stable. Subjects who must discontinue docetaxel due to toxicity
will continue on AB-16B5.
Inclusion Criteria:
- Subjects (male or non-pregnant female) must be ≥ 18 years of age on the day of signing
the informed consent.
- Subjects with a histologically or cytologically confirmed diagnosis of (Stage III-IV)
non-small cell lung cancer (NSCLC) and with at least one measurable lesion defined by
RECIST 1.1.
- Subjects must have experienced a disease progression following treatment with an
anti-PD1 or PD-L1 immune checkpoint antibody and a platinum-containing doublet
treatment, administered simultaneously or sequentially.
- Subjects with a targetable driver mutation in EGFR or ALK gene will be allowed on
trial after failing all available targeted therapies and having experienced a disease
progression following treatment with an anti-PD1 or PD-L1 immune checkpoint antibody
and a platinum-containing doublet treatment, administered simultaneously or
sequentially.
- Subjects must have adequate organ and immune function
- Subjects must have a tumor lesion amenable for biopsies with no contraindication for
biopsy.
- Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of
≤ 2.
- Subjects must have a life expectancy of at least 3 months.
- Subjects must have recovered from the toxic effects resulting from the most recent
cancer treatment to Grade 1 or less. If the subjects underwent major surgery or
received radiation therapy, they must have recovered from the complications and/or
toxicity.
- Female subjects of childbearing potential must have a negative serum pregnancy test
within 72 hours prior to the first dose of study treatment.
- Subjects (both male and female) of reproductive potential must be willing to practice
highly effective methods of contraception throughout the study and for up to 90 days
after the last dose of study medication. Abstinence is acceptable if this is the
subject's usual lifestyle.
- Female subjects are not considered of childbearing potential if they have a history of
surgical sterility or evidence of post-menopausal status defined as any of the
following:
- ≥ 45 years of age and has not had menses for more than 2 years.
- Amenorrhoeic for less than 2 years without hysterectomy and oophorectomy and a
follicle stimulating hormone (FSH) value in the postmenopausal range at
screening.
- Post hysterectomy, oophorectomy or tubal ligation. Documented hysterectomy or
oophorectomy must be confirmed with medical records of the actual procedure or by
ultrasound. Tubal ligation must be confirmed with medical records of the actual
procedure.
- Subjects must understand and be able and willing and likely to fully comply with the
study procedures, including scheduled follow-up, and restrictions.
- Subjects must have given written personally signed and dated informed consent to
participate in the study in accordance with the International Conference on
Harmonization (ICH) Good Clinical Practice (GCP) Guidelines, before completing any
study related procedures.
Exclusion Criteria:
- Subjects who have received prior therapy with AB-16B5.
- Subjects who have received prior therapy with docetaxel for the treatment of NSCLC.
- Subjects who are currently participating or has participated in a study of an
investigational agent or using an investigational device within 21 days prior to the
first dose of study treatment. The 21-day window should be calculated using the last
dose of an antineoplastic investigational agent or last use of an investigational
device with antineoplastic intent.
- Subjects who have received any anti-cancer treatment within 3 weeks or radiation
therapy within 2 weeks prior to receiving the first dose of study treatment or who
have not recovered from adverse events to Grade 1 or less. Subjects with alopecia are
eligible to participate.
- Subjects who are expected to require any other form of systemic or localized
antineoplastic therapy while on the trial. This includes maintenance therapy with
another agent or radiation therapy.
- Subjects who are receiving a dose > 10 mg/day of prednisone (or equivalent) within 7
days prior to the first dose of study treatment or any other form of immunosuppressive
medication (corticosteroid pre-treatment and/or post-treatment of docetaxel is
allowed).
- Subjects who require treatment with a strong CYP3A4 inhibitor (e.g., ketoconazole,
itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir,
ritonavir, saquinavir, telithromycin and voriconazole). Subjects may be included if
there is an alternate treatment with a weak CYP3A4 inhibitor and they are willing to
change at least 7 days prior to the first dose of study treatment.
- Subjects who have another malignancy that is progressing or requires active treatment.
Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
skin or in situ cervical cancer.
- Subjects who have known active central nervous system metastases and/or carcinomatous
meningitis. Subjects with previously treated brain metastases may participate if they
have been clinically stable for at least 2 weeks prior to the first dose of study
treatment, if they have no evidence of new or enlarging brain metastases and if they
are not receiving a dose > 10 mg/day of prednisone (or equivalent) within 7 days prior
to the first dose of study treatment.
- Subjects with clinically significant ECG abnormalities.
- Subjects who have received or will receive a live vaccine within 30 days prior to the
first dose of study treatment.
- Subjects with a known history of human immunodeficiency (HIV).
- Subjects with an active Hepatitis B or C infection.
- Subjects with an active infection requiring antibiotic therapy.
- Subjects with a known history of alcohol or other substance abuse within the last
year.
- Subjects with known hypersensitivity to docetaxel.
- Subjects who have a history or current evidence of any condition, therapy or
laboratory abnormalities that may confound the results of the trial, interfere with
the subject's participation for the full duration of the trial or if it is not in the
best interest of the subject to participate in the trial.
- Subjects with medical, social or psychosocial factors that, in the opinion of the
treating Investigator, could impact the safety or compliance with study procedures.
- Subjects who are pregnant or lactating or who are expecting to conceive or father
children within the projected duration of the trial through 90 days after the last
dose of AB-16B5 or the last dose of docetaxel.
